

FUNDING OPPORTUNITIES SPECIFIC TO THE 2019 NOVEL CORONAVIRUS (2019-NCOV)

Funding notices most relevant to CIRA research are highlighted in yellow. Please note that funding notices are published daily by NIH. Visit [NIH grants and funding page](#) and [NIH COVID-19 funding page](#) for the latest information and to subscribe for updates.

Visit [CIRA's COVID-19 and HIV Resources webpage](#) for information on call for papers, research tools and guidance, and other relevant resources.

Related notices:

- [NOT-OD-20-118](#) (released June 10, 2020): NIH is issuing this notice to highlight the need for and value of data harmonization and data sharing specifically in the context of urgent competitive revisions and administrative supplements producing data to investigate the social, behavioral, economic, and health impacts of the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.
- [NOT-MH-20-061](#) (released June 4, 2020): With this notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus. The goal of this notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

ADMINISTRATIVE SUPPLEMENTS AND URGENT COMPETITIVE REVISIONS FOR RESEARCH ON THE 2019 NOVEL CORONAVIRUS (2019-NCOV)

Some grants may not be eligible to supplement funding. If you are a Yale investigator, please contact Amy Ellis (amy.ellis@yale.edu) at [Yale's Office of Sponsored Projects \(OSP\)](#) for questions regarding eligibility.

Notice Number	Issued by	First Available Due Date	Expiration Date	Funding Opportunities
1. Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-121.html Purpose: This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These	OD, NIMHD, NIA, NEI, NHLBI, NHGRI, NIAAA, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, FIC, NCCIH, NCATS, NCI, SGMRO, THRO, ODP,	August 7, 2020	August 8, 2020	PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

<p>two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. This Testing Research Projects NOSI will support supplements to NIH grantees that are part of large-scale networks, consortia, centers and other current programs that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing.</p>	<p>OBSSR, ORWH, ECHO, NIBIB</p>			
<p>2. Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-119.html Purpose: This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities.</p>	<p>OD, NIMHD, NIA, NEI, NHLBI, NHGRI, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, FIC, NCCIH, NCATS, NCI, SGMRO, THRO, ODP, OBSSR, ORWH, ECHO</p>	<p>July 8, 2020</p>	<p>September 9, 2020</p>	<p>PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</p>

<p>3. Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-120.html Purpose: This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. This Testing Research Projects NOSI will support supplements to individual NIH research awards that include community collaborations or partnerships to support COVID-19 testing (or have the capacity to ramp up quickly) to reach underserved and/or COVID-19 vulnerable populations.</p>	<p>OD, NIMHD, NIA, NEI, NHLBI, NHGRI, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NIGMS, NINDS, NIMH, NINR, NLM, FIC, NCCIH, NCATS, NCI, SGMRO, THRO, ODP, OBSSR, ORWH, ECHO</p>	<p>July 8, 2020</p>	<p>September 9, 2020</p>	<p>PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</p>
<p>4. Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-022.html Key questions include: To what extent do existing interventions slow the spread of COVID-19 in specific populations and geographic hotspots? To what extent do</p>	<p>NIMHD, NEI, NHLBI, NIA, NIAAA, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NIMH, NCCIH, NCATS, SGMRO, ODP, OBSSR, ORWH</p>	<p>June 10, 2020</p>	<p>December 30, 2020</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative</p>

<p>policies, guidelines, and other interventions facilitate adherence and mitigate the multifaceted impacts of COVID-19 on health in populations that experience health disparities and vulnerable groups? Can established models of crisis and disaster response and management be applied to address the needs of health disparity and other vulnerable populations?</p>				<p>Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>5. Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-053.html Purpose: The purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.</p>	<p>NIMH, NEI, NHLBI, NIA, NIAAA, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NINR, NIMHD, NCCIH, NCATS, SGMRO, ODP, OBSSR, ORWH</p>	<p>June 10, 2020</p>	<p>December 30, 2020</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>6. Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html Purpose: NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.</p>	<p>NIDA</p>	<p>March 19, 2020</p>	<p>March 31, 2021</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>

<p>7. Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html Purpose: NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.</p>	<p>NIMH, NIA, NIAAA, NIMHD, ODP</p>	<p>March 27, 2020</p>	<p>April 16, 2021</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to <u>expand the scope</u> of their active grant.</p> <p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully <u>within the scope</u> of the ongoing grant.</p>
<p>8. Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-011.html Purpose: Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation's response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the</p>	<p>NIAAA</p>	<p>May 15, 2020</p>	<p>April 16, 2021</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p> <p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>

<p>groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.</p>				
<p>9. Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html Purpose: The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.</p>	<p>NIMHD, NIA, NIMH, NIAAA</p>	<p>May 01, 2020</p>	<p>May 01, 2021</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p> <p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>10. Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html Purpose: This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-</p>	<p>OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, NICHD, NINR, NHGRI</p>	<p>April 13, 2020</p>	<p>April 1, 2021</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p> <p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative</p>

<p>19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.</p>				<p>Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>11. Administrative Supplements to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for Coronavirus Disease 2019 (COVID-19) – related Research https://grants.nih.gov/grants/guide/notice-files/not-od-20-107.html Purpose: The purpose of this NOSI is to encourage eligible ECHO cohort grantees to apply for this administrative supplement aimed at fostering time-sensitive ECHO-wide Cohort science related to the COVID-19 pandemic. The ECHO Program’s mission is to enhance the health of children for generations to come. Understanding the effects of a broad array of early environmental exposures on child health and development, including issues related to the COVID-19 pandemic, is a priority for the NIH.</p>	<p>Office of The Director, National Institutes of Health (OD)</p>	<p>June 29, 2020</p>	<p>June 30, 2020</p>	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>12. National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html</p>	<p>NCI</p>	<p>April 14, 2020</p>	<p>June 26, 2020</p>	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>

<p>Purpose: The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer.</p>				<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>13. Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/not-at-20-012.html Purpose: The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product-based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial</p>	<p>NCCIH, ORWH</p>	<p>May 22, 2020</p>	<p>August 18, 2020</p>	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p> <p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>

therapies, and Chinese medicine herbal preparations.				
<p>14. Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-011.html Purpose: NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.</p>	NCCIH, NIA, NIAAA	Applications will be accepted on a rolling basis through October 6, 2020 by 5:00 p.m. local time of the applicant organization.	October 7, 2020	<p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p> <p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p>
<p>15. Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html Purpose: National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.</p>	NCATS	June 05, 2020	October 17, 2020	<p>PAR-17-465 Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3) Applicable Receipt Date: June 26, 2020</p> <p>PA-18-462 Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed) Applicable Receipt Date: June 16, 2020, October 16, 2020</p> <p>PAR-18-332 Clinic Testing Therapeutic/Indications</p>

				Pairing Strategies (U01 Clinical Trial Required) Applicable Receipt Dates: June 5, 2020, October 5, 2020
<p>16. Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html</p> <p>Purpose: The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.</p>	NCATS	May 04, 2020	November 11, 2020	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p> <p>PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</p>
<p>17. Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html</p> <p>Purpose: NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:</p> <ul style="list-style-type: none"> - Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS- 	NIGMS	March 25, 2020	February 06, 2021	PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

<p>CoV-2 and other related infectious agents (all relevant grants).</p> <ul style="list-style-type: none"> - Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only). - Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only). 				
<p>18. Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html Purpose: NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives described in the NOSI.</p>	NIAID	March 25, 2020	March 25, 2021	<p>PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</p>
<p>19. Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System https://grants.nih.gov/grants/guide/notice-files/not-ns-20-051.html Purpose: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019</p>	NINDS, NIAAA	May 01, 2020	April 15, 2021	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p> <p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and</p>

<p>(COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS's scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.</p>				<p>Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>
<p>20. Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html Purpose: NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.</p>	<p>NIA, NIMH, NIAAA</p>	<p>April 06, 2020</p>	<p>May 01, 2021</p>	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p> <p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>
<p>21. NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/not-es-20-020.html Purpose: NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the</p>	<p>NIEHS</p>	<p>May 01, 2020</p>	<p>May 04, 2021</p>	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</p> <p>PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>

<p>role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				<p>If you are applying for a new R21 grant that does not build off of an existing NIEHS grant, apply to RFA-ES-19-011 "Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)", provided the time-sensitive criteria described therein are met.</p>
<p>22. Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html Purpose: National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.</p>	<p>NCATS</p>	<p>May 04, 2020</p>	<p>July 10, 2021</p>	<p>PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) Applicable Receipt Dates: May 4, 2020, November 2, 2020</p> <p>PAR-19-099 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional) Applicable Receipt Dates: July 10, 2020, November 9, 2020, March 8, 2021, July 9, 2021</p> <p>PAR-19-100 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation</p>

				<p>Awards (R21 Clinical Trial Optional) Applicable Receipt Dates: July 10, 2020, November 9, 2020, March 8, 2021, July 9, 2021</p> <p>PAR-19-337 Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional). Applicable Receipt Date: September 25, 2020</p>
<p>23. Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) https://grants.nih.gov/grants/guide/notice-files/not-ai-20-051.html Purpose: In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address the following research areas of interest:</p> <ul style="list-style-type: none"> • Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission; • Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence; • Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2; • Development of SARS-COV-2 therapeutic candidates, especially broad-spectrum 	NIAID	June 16, 2020	September 08, 2021	<p>PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</p> <p>PA-19-272 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)</p> <p>PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)</p>

<p>therapeutics against multiple coronavirus strains;</p> <ul style="list-style-type: none"> • Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for T cell activation or antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and studies to examine duration of protection or the potential for reinfection; and 				
<p>24. PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Projects</p> <p>Research Projects: https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-research-awards</p> <p>Engagement Awards: https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-engagement-awards</p> <p>Dissemination and Implementation Awards: https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-dissemination-implementation-awards</p>	PCORI	<p>May 1, 2020</p> <p>April 20, 2020</p> <p>May 1, 2020</p>	<p>Enhancement proposals will be considered on a rolling basis.</p>	

FUNDING OPPORTUNITY ANNOUNCEMENTS

Below are funding opportunities that solicit applications for new grants responsive to the COVID-19 that do not build off existing grants.

Notice Number	Issued by	Open Date (Earliest Submission Date)	Application Due Date	Purpose
1. Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-038.html	NCI, NIAID	June 22, 2020	July 22, 2020	The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.
2. Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-039.html	NCI, NIAID	June 22, 2020	July 22, 2020	The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize

				<p>the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.</p>
<p>3. NIH Director's Emergency Early Independence Awards (DP5 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-021.html</p>	<p>Office of Strategic Coordination (Common Fund)</p>	<p>August 4, 2020</p>	<p>AIDS Application Due Date: September 4, 2020</p>	<p>This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Early Independence Award applications must be submitted in response to RFA-RM-20-014.</p> <p>The NIH Director's Early Independence Award (a component of the High-Risk, High-Reward Research program of the NIH Common Fund) supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-</p>

				graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement.
4. Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-013.html	Multiple, see FOA	July 8, 2020	August 7, 2020	This emergency cooperative agreement funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be

				implemented to decrease these disparities. This FOA seeks to fund a single Coordination and Data Collection Center (CDCC) as an integral part of the consortium.
<p>5. NIH Director's Emergency Transformative Research Awards (R01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html</p>	Office of Strategic Coordination (Common Fund)	August 30, 2020	AIDS Application Due Date: September 30, 2020	<p>This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013.</p> <p>The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse</p>

				backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director's Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
6. Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PAR-20-237.html	Multiple, see FOA	July 28, 2020	AIDS Application Due Date(s): August 28, 2020; December 1, 2020	This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the

				pandemic on the health of these groups.
<p>7. NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) https://grants.nih.gov/grants/guide/pa-files/PAR-20-234.html</p>	NIA	June 1, 2020	Application Due Date(s): July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021	This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19).
<p>8. Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-19-373.html</p>	Multiple, see FOA	February 17, 2020	Application Due Date(s): June 8, 2020; March 17, 2021	<p>This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans.</p> <p>See Notice NOT-OD-20-103 for additional areas of focus</p>

				especially of interest that includes COVID-19.
<p>9. Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-19-384.html</p>	Multiple, see FOA	February 17, 2020	<p>Application Due Date(s): June 8, 2020; March 17, 2021</p> <p>AIDS Application Due Date(s): March 17, 2021</p>	<p>This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as “prospective basic science studies involving human participants” that meet the NIH definition of basic research and fall within the NIH definition of a clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate</p>

				<p>independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.</p> <p>See Notice NOT-OD-20-103 for additional areas of focus especially of interest that includes COVID-19.</p>
<p>10. Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</p> <p>R21 Clinical Trial Not Allowed: https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html</p> <p>R01 Clinical Trial Not Allowed: https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html</p>	NIAID	April 30, 2020	Applications will be accepted on a rolling basis (expiration date: April 30, 2021)	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).</p>